Turbine is virtualizing biological experiments with AI to accelerate drug discovery and improve clinical translatability. Using its foundational virtual cell model powered by its lab-in-the-loop, Turbine creates virtual copies of experimental assays. Running experiments at computational speed and scale allows researchers to test millions of ideas, beyond physical lab constraints, to understand biological drivers of disease. Working with scientists at leading biopharma like MSD (Merck & Co.), AstraZeneca and Bayer, Turbine’s virtual assays have rationalized experiments across more than 30 discovery programs. Backed by leading tech and industry investors like Accel, MSD Global Health Innovation Fund, Interactive Venture Partners and Beiersdorf, Turbine is turning biology into an engineering discipline.
TubeWriter
TubeWriter labeling systems is a full-feature instrument for printing directly at high-speed on the sides and caps of plastic, glass, and curved surfaces, including tubes, vials, slides, plates and custom labware. It is designed to address automating laboratory printing for assays, protocols and experiments. TubeWriter labeling withstands the harshest of lab conditions; resistant to chemical solvents and surviving long-term storage at -80C and liquid nitrogen. | TubeWriter is an automated labeling systems that prints directly on the surface of any labware eliminating the need for sticky labels. For laboratories that perform medium to high-throughput applications struggling with manual labeling or paper labels, the TubeWriter prints directly on the sides and caps of tubes, vials, plates and unique labware. TubeWriter prints text, images, and barcodes using UV-curable ink that withstands extreme lab conditions, most harsh chemicals and long-term storage at -80C and liquid nitrogen.
TOKYO OHKA KOGYO CO., LTD.
SIEVEWELL is an innovative single‑cell arraying platform designed to precisely isolate, position, and analyze individual cells in a high‑throughput and user‑friendly manner. Built around a robust nanowell architecture, SIEVEWELL enables efficient capture of single cells with minimal doublets, making it ideal for applications that require accurate cell‑to‑cell resolution. The platform is optimized for a wide range of cell types, including suspension and primary cells, and supports controlled co‑culture experiments such as target–effector pairing studies. Its gravity‑based loading process eliminates the need for complex microfluidic control systems, allowing researchers to achieve reproducible single‑cell occupancy using standard laboratory equipment. SIEVEWELL is fully compatible with automated imaging systems and downstream assays, including fluorescence‑based viability, functional readouts, and time‑lapse observations. The transparent substrate and standardized layout enable seamless integration with high‑content imaging platforms, facilitating quantitative single‑cell analysis at scale. Designed with simplicity, reproducibility, and flexibility in mind, SIEVEWELL accelerates single‑cell research by reducing experimental complexity while maintaining high data quality. It is an ideal solution for immunology, oncology, cell therapy development, and functional single‑cell assays where precise spatial control and reliable single‑cell data are essential. | SIEVEWELL™ is high density single cell arraying device. This device has a self-standing filter membrane with 370,000(type Hex20) or 90,000(type Hex50) nanowells. SIEVEWELL™ is designed to trap cells at a high single cell rate. Fluidic system or instrument is not required. SIEVEWELL™ is a useful tool for single cell culture, staining, imaging and assay.
TissUse GmbH
TissUse is a Berlin, Germany-based, biotechnology company, which has developed a unique “Multi-Organ-Chip” platform that provides unparalleled preclinical insight on a systemic level using human tissues. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse’s Multi-Organ-Chips provide a new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials. TissUse’s Multi-Organ-Chips have been utilized in a large variety of applications including drug development, cosmetics, food and nutrition and consumer products since 2012.
Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 2,800 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives. | Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are committed to moving our customers through their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 100 subsidiaries and 180 service locations, with over 10,000 employees across 54 countries in Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables boundless possibility for healthcare industry, embracing challenges to fulfill our commitment to serve unmet patients’ needs, and eventually saving lives. | Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,200 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.
THEWELL BIOSCIENCE INC.
TheWell Bioscience is a biotechnology company delivering an end-to-end xeno-free platform for robust, reproducible 3D cell models. Its integrated xeno-free ecosystem includes VitroGel® hydrogels, RocketCell™ media, VitroPrime™ cultureware, CytoGrow™ growth factors, and Cyto3D® reagents. By eliminating animal-derived variability, the company provides defined, scalable solutions supporting organoid research, precision medicine, cell therapy, biomanufacturing, and New Approach Methodologies (NAMs).
TETHIS SPA
Tethis S.p.A., an Italian diagnostic firm, has pioneered titanium dioxide–nanocoated SmartBioSurface® slides that enable in‑situ analysis of typically non‑adherent cells – including primary cells, stem cells, and PBMCs. These slides are ideally suited for multiplex and multiomic assays, advanced spatial biology techniques, and precise single‑cell laser‑capture microdissection. In addition, Tethis has developed See.d®, an automated instrument for pre‑analytical sample preparation in liquid biopsy. See.d® introduces a new level of standardization and reliability by fully automating plasma and cytology sample processing – addressing two major unmet needs in liquid biopsy workflows: the lack of reproducible, standardized pre‑analytical protocols and the difficulty of visualizing and analysing rare tumor and immune cells on microscopy slides.
Tecan
At Tecan we are driven to improve people’s lives and health. We do this by empowering our customers to scale healthcare innovation globally from life science to the clinic. We collaborate with our customers in healthcare and the life sciences, from early-stage innovation through project implementation and beyond. We deliver the products, services and solutions that make lab processes and medical procedures precise, reproducible and compliant. This leads to scalable outcomes that are further reaching and ever more valuable to humankind. | Tecan is a global leader in life sciences and diagnostics, offering cutting-edge solutions that span genomics, automation, and personalized medical research. With a strong focus on workflow integration, Tecan delivers modular platforms and reagents that support every step of the genomics pipeline—from nucleic acid purification and quantification to PCR setup and next-generation sequencing (NGS) library preparation. Tecan’s automation systems, including MagicPrep® NGS and DreamPrep® NGS, provide walkaway solutions that simplify complex protocols, reduce errors, and increase throughput. These platforms enable broad and targeted genomic applications, which streamlines sequencing workflows for infectious disease and oncology research. Tecan’s commitment to standardization, scalability, and sustainability makes it a trusted partner for academic, clinical, and industrial research labs worldwide. By integrating automation with advanced reagents and collaborative development, Tecan is helping transform research into real-world medical impact. | Tecan supports the full product journey for complex MedTech, IVD, and life science systems, from critical components through development and manufacturing. Our teams specialize in high-mix, high-complexity programs that require disciplined processes and dependable execution. Through our contract manufacturing capabilities, we combine structured design transfer and vPoke® computer-directed assembly to deliver consistent results from pilot builds through scale. In parallel, our Cavro® components team provides precision liquid handling solutions that form the foundation of many complex instruments. With manufacturing in the US and Malaysia, FDA-approved facilities, and decades of experience across regulated industries, Tecan helps teams move forward with confidence, predictability, and long-term support. | Tecan is uniquely qualified to solve your most difficult technology and product-design problems. Our approach blends fundamental science and engineering to deliver limitless technology development. We take your ideas from concept to advanced functional prototype quickly, accurately and cost-effectively with our fixed price engagement model.
Takara Bio Inc.
Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is committed to helping scientists break new ground with innovative technologies for the life sciences. Our extensive portfolio of reagents, instruments, and services supports advancements across many areas of research, development, frontline diagnostics, and clinical applications. Our parent company, Takara Bio Inc., is a leading provider of biotechnology equipment and reagents, and conducts research and development activities involving gene- and cell-based therapies. Together with its subsidiaries, Takara Bio Inc. is committed to preventing disease and improving the quality of life for all through the use of biotechnology.